This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SmileDirectClub (SDC) Reels Under Cyber Attack, Pandemic Woes
by Zacks Equity Research
SmileDirectClub (SDC) apprehends systems outage to have an adverse impact on its second-quarter revenues to the tune of approximately $10-$15 million.
Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.
Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake
by Zacks Equity Research
Boston Scientific (BSX) currently holds an equity stake of roughly 27%.
Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues
by Zacks Equity Research
Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.
OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal
by Zacks Equity Research
OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.
NEOGEN (NEOG) Enhances Aquaculture Genotyping With New Pact
by Zacks Equity Research
NEOGEN (NEOG) together with CAT can enable members of the aquaculture sector to make more informed breeding decisions.
Medtronic (MDT) Reports First Surgery With Hugo RAS System (Revised)
by Zacks Equity Research
Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.
LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research
by Zacks Equity Research
The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.
Hologic (HOLX) Gets European Nod for Aptima CMV Quant Assay
by Zacks Equity Research
Hologic's (HOLX) Aptima CMV Quant assay is intended to help in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.
Medtronic (MDT) Reports First Surgery With Hugo RAS System
by Zacks Equity Research
Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.
Quest Diagnostics (DGX) Unveils Corporate Responsibility Report
by Zacks Equity Research
Per Quest Diagnostics' (DGX) 2020 Corporate Responsibility Report, it has expanded COVID-19 capacity throughout the year, performing 30 million COVID-19 molecular tests and serology tests.
Medtronic (MDT) Gets Expanded FDA Nod for Cryoablation Catheters
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation Catheters offer safe and effective substitute to antiarrhythmic drug therapy for the prevention of atrial arrythmia recurrence.
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and bullish 2021 earnings guidance.
Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays
by Zacks Equity Research
Illumina (ILMN) derives benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies.
Hologic (HOLX) to Beat Post-COVID Woes With Mobidiag Buyout
by Zacks Equity Research
Hologic (HOLX) management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenges faced in multiplexed point-of-care molecular testing.
NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry
by Zacks Equity Research
NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.
Abbott's (ABT) Base Business Recovers, Lowered View Concerns
by Zacks Equity Research
According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.
Thermo Fisher's (TMO) New Launch Boosts Preclinical Development
by Zacks Equity Research
Thermo Fisher's (TMO) enhanced Quick to Clinic solution provides balance of speed and quality to accelerate and advance DNA to Investigational New Drug in as less as 13 months.
CVS Health (CVS) Digital Tools Gain Steam Amid COVID-19 Crisis
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is more relevant in the current environment as people are increasingly using technology while staying indoors.
Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
by Zacks Equity Research
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid CALID Group growth potential and raised 2021 financial guidance.
Walgreens' (WBA) Retail Products Now Available on Uber Eats
by Zacks Equity Research
Walgreens (WBA) now offers on-demand product delivery through an expanded collaboration with Uber.
Phirbo (PAHC) Nutritional Specialties Grow, Vaccine Sales Dip
by Zacks Equity Research
Currently, Phirbo (PAHC) is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets.